The metabolic syndrome (MS) is a common risk factor for cardiovascular disease and type-2 diabetes.
Introduction
The metabolic syndrome (MS), characterized by the clustering of hypertension, insulin resistance, and dyslipidemia, is a common risk factor for cardiovascular disease and type-2 diabetes ( 1 , 2 ) . To achieve optimal prevention of cardiovascular outcomes in hypertensive patients, a multi-factorial approach is required, combining lifestyle modification, blood pressure lowering, and control of dyslipidemia. In addition, prevention of type-2 diabetes has become recognized as an important component of cardiovascular risk reduction in patients with essential hypertension ( 3 , 4 ) . Since insulin resistance is the core malfunction that leads eventually to the development of type-2 diabetes, improving insulin sensitivity can be beneficial and contribute to lowering the risk for developing diabe-tes. Activation of the renin-angiotensin system (RAS) contributes to the development of insulin resistance. β -Cell dysfunction due to angiotensin-mediated increases in oxidative stress, inflammation, and free fatty acids concentrations, as well as glucotoxicity, lipotoxicity, and advanced glycation, potentially contribute to insulin resistance related to RAS activation ( 5 ) . Although a number of clinical and experimental studies suggested that angiotensin II receptor antagonists can improve insulin sensitivity and decrease the incidence of new-onset type-2 diabetes in patients with hypertension, the exact mechanisms underlying these beneficial effects are not fully understood ( 6 -8 ) .
Adiponectin has been shown to have insulin-sensitizing properties in murine models ( 9 -13 ) . Several studies have shown that some of the beneficial effects of peroxisome proliferator-activated receptor γ (PPAR γ ) activation are mediated by the increase in adiponectin levels ( 14 , 15 ) . A few recent studies found that telmisartan, an angiotensin II type 1 (AT1) receptor antagonist, is a partial PPAR γ nuclear receptor agonist ( 16 -19 ) . However, there are conflicting data regarding telmisartan's in vivo effects on metabolic parameters in animal models of the metabolic syndrome (16, 20) . Therefore, we assessed telmisartan's effects on adiponectin and metabolic indices in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.
Methods
Twenty-four male Sprague-Dawley rats weighing 220 to 250 g were used in the study. A control group (n= 8) was fed a normal chow diet. Sixteen rats were fed a fructose-enriched diet (Teklad-Harlan, Madison, USA) consisting of 21% protein, 5% fat, 60% carbohydrate, 0.49% sodium, and 0.49% potassium, for 5 weeks. The rats fed the fructose-enriched diet (FED) were further subdivided into two groups: one group of 8 rats was given FED for 5 weeks (nontreated group) while the other group of 8 rats was given FED for 5 weeks, with telmisartan 5 mg/kg/day administered in the last 2 weeks of the experiment (treated group).
The experiments were conducted according to the Guidelines for Animal Care and Treatment of the hospital's Animal Ethics Committee. The rats were maintained in a temperature-controlled room (22°C) and kept on a 14/10 light/dark cycle. Telmisartan was administered by dissolving the commercially available drug in the drinking water at an initial concentration of 40 mg/L. Because fluid intake was not scaled linearly with body weight, drug intake based on body weight tended to decline over time. Therefore, the drug concentration in the drinking water was increased during the course of the study every week to maintain the scheduled dosing. The fluid intake was similar in all the groups. Body weight was measured before the start of the experiment and then weekly. Systolic blood pressure (SBP) was measured weekly in conscious rats by the indirect tail-cuff method using an electrosphygmo-manometer and a pneumatic pulse transducer (Narco Biosystems, Houston, USA). The mean of five consecutive readings was recorded.
Blood samples from a retro-orbital sinus puncture were taken, under light anesthesia with isoflurane after 5 h of fasting, at the beginning of the experiment and after 3 and 5 weeks. Plasma adiponectin concentrations were determined using an RIA kit (Linco Research, Billerica, USA). Insulin levels were assessed using a rat insulin ELISA kit (Mercodia, Uppsala, Sweden), and triglyceride levels were assayed with an automated analyzer of an enzymatic colorimetric reaction (Olympus AU 270, Hamburg, Germany).
Data Analysis
Results are presented as mean±SEM. Differences between series of data were assessed by two-way paired and unpaired Student's t-tests for group comparison. A p value of less than 0.05 was considered significant.
Results

Effects of Fructose-Enriched Diet on Parameters of the Metabolic Syndrome
Baseline parameters were the same for all three groups. At 3 weeks, the chow and fructose-fed groups showed similar weight gains. Three weeks of the FED induced the MS as manifested by increases in blood pressure (from 130±1 to 145±1 mmHg, p< 0.05), plasma insulin (from 0.26±0.02 to 0.38±0.03 ng/mL, p< 0.05), and triglycerides (from 102±6 to 184±13 mg/dL, p< 0.05) ( Fig. 1A-C ). Plasma adiponectin did not change in chow-fed rats. However, similar to a finding in our recent report (21), 3 weeks of fructose feeding increased plasma adiponectin levels, from 3.1±0.3 to 4.8±0.6 μg/mL (p < 0.05) ( Fig. 1D ).
Telmisartan's Effects on Parameters of the Metabolic Syndrome in Fructose-Fed Rats
Telmisartan administration significantly decreased SBP (148±2 in nontreated vs. 125±2 mmHg in telmisartan-treated rats) ( Fig. 2) . Triglyceride levels were reduced to 146±18 compared to 285±23 mg/dL in nontreated rats, and insulin levels to 0.41±0.07 compared to 0.68±0.08 ng/mL in nontreated rats (p < 0.05 for all variables) ( Fig. 2) . At 5 weeks, body weight was similar in chow and fructose-fed rats, but was slightly, not significantly, lower in telmisartan-treated rats than in nontreated rats. However, telmisartan attenuated the increase in body weight from weeks 3 to 5 significantly (32 ±2.0, 26 ±2.0, and 12 ±3.0 g in control, nontreated, and telmisartan-treated rats, respectively; p < 0.05 compared to fructose-fed rats).
Telmisartan's Effect on Plasma Adiponectin Levels
At 3 weeks, plasma levels of adiponectin in fructose-fed rats were similar to those in fructose-fed rats designated for telmisartan treatment, and higher than those in chow-fed rats (4.8±0.6; 5.5±0.7 and 3.3±0.1 μg/mL, respectively, p < 0.05). Telmisartan administration during the last 2 weeks of the experiment did not affect plasma adiponectin levels (4.6±0.5 and 4.5±0.3 μg/mL in fructose-fed rats not treated with telmisartan and telmisartan-treated rats, respectively) ( Fig. 2D ).
Discussion
Accumulating data have shown that PPARγ activation increases adiponectin levels (14, 15) . Recent studies suggested that telmisartan, an angiotensin II receptor antagonist, is also a partial PPARγ agonist (16, 17) . Therefore, it was expected that telmisartan would increase adiponectin levels. Our results showed that telmisartan can reverse fructoseinduced hypertension, hyperinsulinemia, and hypertriglyceridemia. However, these beneficial effects were not coupled with increased plasma adiponectin levels. Previous animal studies examined telmisartan's effect on the metabolic profile in a dietary model of insulin resistance. In male Sprague-Dawley rats fed a high-fat, high carbohydrate diet for 3 months, telmisartan given along with the diet attenuated weight gain as well as glucose, insulin, and triglyceride levels (16, 22) . A recently published study questioned whether the reported effects of angiotensin receptor blockers on insulin sensitivity may occur through modulation of the nuclear receptor PPARγ (20) . Telmisartan treatment resulted in significant PPARγ agonism in vitro. However, when tested in vivo, telmisartan treatment had no effect on insulin sensitivity (20) . The fructose-fed rat model is a commonly used model that mimics human MS in many aspects, including hypertension, hypertriglyceridemia, insulin resistance, and compensatory hyperinsulinemia, but it is not associated with obesity. In the present study, adiponectin levels increased following 3 weeks of fructose feeding. In fact, we recently demonstrated that metabolic stress with a high-carbohydrate diet increased adiponectin levels in two rat models of hypertension and insulin resistance (21) . This may be a transitory compensatory mechanism or it may reflect a decrease in adiponectin's ability to interact with its receptors as a sign of target organ resistance to adiponectin. The present study is the first to look at telmisartan's effect on established hypertension and insulin resistance using an environmental and physiologic induction in genetically susceptible rats. In this study, telmisartan effectively treated fructose-induced hypertension, hypertriglyceridemia, and hyperinsulinemia. However, telmisartan did not affect plasma adiponectin, a protein whose levels are known to increase with existing PPARγ agonists and to correlate with insulin sensitivity (23) (24) (25) (26) . We recently showed in fructose fed rats that the PPARγ agonist rosiglitazone improved the metabolic profile to a degree similar to telmisartan, but with increases in plasma adiponectin levels and gene expression (15) . Therefore, it is unlikely that adiponectin mediates telmisartan's beneficial effect on metabolic parameters. Telmisartan may induce its beneficial metabolic effects by directly inhibiting the AT1 receptor. Indeed, several studies have established the notion that AT1 receptor stimulation by angiotensin II contributes to insulin resistance and its associated deleterious metabolic profile (5, 6) . Therefore, the AT1 receptor blockade ameliorates these effects and partially explains the beneficial effects of telmisartan on fructoseinduced insulin resistance. Similar to our findings with telmisartan, a few other studies have shown favorable metabolic effects of other ARBs in fructose-fed rats (27) (28) (29) . Collec- tively, these data indicate that the beneficial metabolic effect is not telmisartan-specific but rather is associated with AT1 receptor antagonism as a class effect of ARBs. The RAS blockade's beneficial effect on insulin resistance has been explained partially by haemodynamic effects, with improved delivery of insulin and glucose to peripheral tissues, as well as by direct effects on glucose transport and insulin signaling pathways (6) . Therefore, normalization of blood pressure by telmisartan in fructose-fed rats could contribute to improved insulin action and a better metabolic profile. However, previous work in our lab has shown that lowering blood pressure in fructose-fed rats by the use of other antihypertensive drugs, such as calcium channel blockers (30) , hydrochlorothiazide, or β-blockers (unpublished data), has not had a metabolic impact, suggesting that telmisartan improved insulin resistance via blood pressure-independent mechanisms. In addition to the AT1 receptor, the angiotensin II type 2 (AT2) receptor may play a role in telmisartan's beneficial effect in fructose-fed rats. Indeed, it was reported that mice lacking Ang II type 1a receptor exhibited an attenuation of dietinduced weight gain and adiposity through increased energy expenditure (31) . Mori et al. recently suggested that the AT2 receptor is important for the regulation of energy homeostasis and may be responsible for the attenuation of adiposity and insulin resistance by telmisartan (32) . The AT2 receptor's potential contribution to telmisartan's beneficial effect in fructose-fed rats is beyond the scope of this report, and future studies may examine the possible effect of an AT2 receptor antagonist with or without telmisartan on variables of metabolic syndrome in fructose-fed rats. Another possible mechanism by which ARBs may exert their beneficial effects on insulin resistance is their potential to alter adipocyte size. Ang II inhibits the differentiation of adipocytes and increases the number of large adipocytes (33) . Therefore, AT1 receptor antagonism can counteract the effect of Ang II, promoting the differentiation and mobilization of preadipocytes to increase the number of small, insulin-sensitive adipocytes. Indeed, treatment with various ARBs has been reported to downsize adipocytes and improve insulin resistance (32, 34) . We did not measure adipocyte size, which is a study limitation. In addition, it is possible that telmisartan improved the impairment of hepatic transduction of the leptin signal, which was recently reported to play a role in fructose-induced insulin resistance in rats (35) . Further studies need to be conducted in order to address these issues.
In summary, we showed that telmisartan effectively treated fructose-induced hypertension, hyperinsulinemia, and hypertriglyceridemia without increasing adiponectin, a marker of in vivo PPARγ activation. Further studies will elucidate the molecular mechanism by which telmisartan reversed the deleterious metabolic affects in this model.
